YKG-1Homo sapiens (Human)Cancer cell line

Also known as: YKG1

🤖 AI SummaryBased on 7 publications

Quick Overview

Human glioblastoma cell line with genetic and molecular characteristics.

Detailed Summary

The YKG-1 cell line is a human glioblastoma-derived cell line established from a surgical specimen. It expresses glial fibrillary acidic (GFA) and S-100 proteins, indicating its glial origin. Chromosome analysis revealed a homogeneously staining region (HSR) on a marker chromosome, suggesting potential amplification of oncogenes. The cell line exhibits characteristics of glioblastoma, including high levels of transforming growth factors (TGFs), which may play a role in tumor progression. YKG-1 is used in research to study glioma biology, genetic alterations, and therapeutic responses.

Research Applications

Glioblastoma researchGenetic and molecular characterizationTransforming growth factor (TGF) studies

Key Characteristics

Expression of GFA and S-100 proteinsPresence of homogeneously staining region (HSR)High levels of TGFs
Generated on 6/17/2025

Basic Information

Database IDCVCL_1796
SpeciesHomo sapiens (Human)
Tissue SourceBrain, right temporo-occipital lobe

Donor Information

Age53
Age CategoryAdult
SexFemale

Disease Information

DiseaseGlioblastoma
LineageCNS/Brain
SubtypeGlioblastoma
OncoTree CodeGB

DepMap Information

Source TypeHSRRB
Source IDACH-000570_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Trp146_Ser149delinsCys (c.438_446delGGTTGATTC)Heterozygous-Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12
D13S317
8,12
D16S539
11
D5S818
10,11
D7S820
10,11
TH01
6,9
TPOX
11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.

Aoyagi M., Ohno K., Imoto I., Inazawa J.

Cancer Sci. 96:676-683(2005).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

Establishment of a human glioma cell line bearing a homogeneously staining chromosomal region and releasing alpha- and beta-type transforming growth factors.

Morita H., Yasumitsu H., Umeda M., Nagashima Y.

Acta Neuropathol. 79:30-36(1989).